Cevian Capital disclosed a stake above 11% in Smith & Nephew on Thursday, marking the third activist fund to take a material position in the London-listed medical device maker in the past eighteen months. The Stockholm-based firm now holds 157.4 million shares worth approximately $1.27 billion at current trading levels, sitting alongside Elliott Management's 8.1% and Polaris Capital Management's 5.3%. Combined, the three activists control over 24% of the company that has underperformed the MSCI World Healthcare Equipment Index by 37 percentage points since January 2020.
Smith & Nephew manufactures orthopedic reconstruction devices, advanced wound care products, and sports medicine equipment across 100 countries, generating $5.2 billion in trailing twelve-month revenue. The company has struggled with margin compression in its core knee and hip implant divisions, posting operating margins of 16.2% in the most recent quarter versus peer group averages near 23%. Management attributed the gap to integration costs from prior acquisitions and slower-than-expected adoption of its Cori robotic surgical platform, which has captured only 2.1% of the U.S. knee replacement market since its 2020 launch. Shares trade at 11.4x forward earnings, a 31% discount to Stryker and Zimmer Biomet.
Cevian's move above the 10% threshold triggers UK disclosure requirements and suggests the firm intends to coordinate with Elliott and Polaris rather than file independently. Elliott first disclosed its position in September 2023 and has since secured two board seats, including former Medtronic executive Gary Guthart. Polaris entered four months later with a public letter demanding portfolio rationalization and cost structure overhaul. The three funds share a common thesis: Smith & Nephew's diversified structure masks underperformance in each segment, and the company would generate higher returns as two separate entities—orthopedics and advanced wound management. Precedent exists. Zimmer Biomet spun off its spine division in 2021 and saw shares climb 48% in the following eighteen months. Johnson & Johnson separated its consumer health business in 2023 under similar activist pressure and now trades at a 19% premium to its pre-split multiple.
Operators should watch for a formal separation proposal at the company's February investor day, where management has promised to address capital allocation strategy. Elliott's board representatives are expected to present a detailed operational review comparing Smith & Nephew's segment-level returns against pure-play competitors. If the activists push for immediate action, expect a strategic review announcement by mid-March and formal spin documentation by June, assuming board alignment. Credit Suisse estimated a sum-of-the-parts valuation at $16.50 per share, 27% above current levels, with the orthopedics business likely commanding a 14-15x EBITDA multiple in a sale process.
Cevian typically holds positions for four to six years and has executed eleven successful operational turnarounds in European healthcare and industrials since 2015, including Bilfinger and Atos. The firm's entry at this stake size—above passive threshold, below control trigger—indicates confidence in a negotiated outcome rather than a proxy fight. Smith & Nephew's next earnings call is scheduled for February 20.